PeptiDream Zukünftiges Wachstum
Future Kriterienprüfungen 4/6
PeptiDream wird ein jährliches Gewinn- und Umsatzwachstum von 38.4% bzw. 18.3% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 38.4% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 11% betragen.
Wichtige Informationen
38.4%
Wachstumsrate der Gewinne
38.37%
EPS-Wachstumsrate
| Biotechs Gewinnwachstum | 34.9% |
| Wachstumsrate der Einnahmen | 18.3% |
| Zukünftige Eigenkapitalrendite | 11.03% |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 07 Sep 2026 |
Jüngste Aktualisierungen zum künftigen Wachstum
Analyseartikel • Aug 14
The PeptiDream Inc. (TSE:4587) Half-Yearly Results Are Out And Analysts Have Published New Forecasts
PeptiDream Inc. ( TSE:4587 ) just released its latest half-yearly report and things are not looking great. It was not a...Analyseartikel • Feb 18
Analysts Have Lowered Expectations For PeptiDream Inc. (TSE:4587) After Its Latest Results
There's been a notable change in appetite for PeptiDream Inc. ( TSE:4587 ) shares in the week since its yearly report...Analyseartikel • Feb 17
Earnings Miss: PeptiDream Inc. Missed EPS By 5.6% And Analysts Are Revising Their Forecasts
It's been a pretty great week for PeptiDream Inc. ( TSE:4587 ) shareholders, with its shares surging 18% to JP¥2,328 in...Recent updates
Analyseartikel • Aug 14
The PeptiDream Inc. (TSE:4587) Half-Yearly Results Are Out And Analysts Have Published New Forecasts
PeptiDream Inc. ( TSE:4587 ) just released its latest half-yearly report and things are not looking great. It was not a...
Narrative-Update • Jul 22
4587: Radiopharmaceutical And Theranostic Pipeline Will Support Future Upside
Analysts have revised their price target on PeptiDream from ¥1,600 to ¥1,100, citing updated assumptions regarding fair value, discount rate, revenue growth, profit margin, and future P/E. What’s in the News for PeptiDream Curium Group, PeptiDream and wholly owned subsidiary PDRadiopharma completed patient dosing in a registrational Phase 2 trial in Japan for 64Cu-PSMA-I&T, a PET radiopharmaceutical targeting PSMA for prostate cancer diagnosis, under their existing collaboration (source: Key Developments).
Narrative-Update • Jun 16
4587: Radiopharmaceutical Pipeline Progress Will Drive Future Upside
Analysts have maintained their ¥4,400 price target on PeptiDream, citing updated assumptions for discount rate, revenue growth, profit margin and future P/E that refine their valuation framework without changing the headline target. What’s in the News for PeptiDream PeptiDream announced first patient dosing in a first in human Phase 0 PET/CT imaging study of Cu-PD-29875 targeting Claudin 18.2 in gastric cancer and gastroesophageal junction cancer.
Narrative-Update • Jun 02
4587: Out Licensing Progress And Phase 1 Milestones Will Support Long Term Earnings Visibility
Analysts have trimmed their view on PeptiDream, with the price target moving from ¥2,700 to ¥1,600, as they point to slower than anticipated progress in product out-licensing. What's in the News Asahi Kasei Therapeutics, a collaboration partner of PeptiDream, has started a Phase 1 clinical trial of AK1940, a selective TNFR1 inhibitor discovered using PeptiDream’s PDPS technology.Narrative-Update • May 08
4587: Out Licensing Progress And Autoimmune Pipeline Will Support Future Upside
Analysts have trimmed their price target on PeptiDream to ¥1,600 from ¥2,600, citing slower than expected progress in product out licensing and adjustments to fair value, discount rate, revenue growth, profit margin and future P/E assumptions. Analyst Commentary Bearish analysts are flagging that the lower ¥1,600 price target reflects reduced confidence in how quickly PeptiDream can execute on its product out licensing plans and convert its pipeline into revenue.Narrative-Update • Apr 23
4587: Out Licensing Milestones Will Eventually Support Stronger Long Term Earnings Visibility
Analysts have reduced their price target on PeptiDream to ¥1,600 from ¥2,700, citing slower than expected progress in product out-licensing as the main reason for the adjustment. Analyst Commentary Bullish Takeaways Bullish analysts still see value at the revised price target of ¥1,600, arguing that expectations now better reflect the current pace of out-licensing activity.Narrative-Update • Apr 08
4587: Out Licensing Progress Will Support Stronger Long Term Earnings Visibility
Analysts have lowered their price target on PeptiDream to ¥2,825 from ¥3,008, citing slightly reduced fair value assumptions following slower than expected product out licensing, as reflected in updated discount rate, revenue growth, profit margin, and future P/E inputs. Analyst Commentary Recent research points to a more cautious stance on PeptiDream, with rating and target price adjustments linked mainly to timing risks around product out licensing.Narrative-Update • Mar 25
4587: Out Licensing Progress And 2026 Earnings Targets Will Drive Future Upside
Analysts have modestly raised their fair value estimate for PeptiDream to ¥4,400 from ¥4,255, citing updated assumptions around discount rate, revenue growth, profit margin, and forward P/E, even as some have turned more cautious with a lower Street price target of ¥1,600 reflecting slower than expected product out licensing. Analyst Commentary Recent Street commentary highlights a mix of caution on timing of product out licensing and incremental confidence in PeptiDream's long term potential, reflected in the modest lift in fair value estimates despite a lower Street price target concentrated around ¥1,600.Narrative-Update • Mar 10
4587: Oral Autoimmune Pipeline And siRNA Milestones Will Support Stronger Long Term Outlook
Analysts now set their PeptiDream price target at ¥3,008, down slightly from ¥3,033, reflecting updated assumptions around discount rate, revenue growth, profit margin, and future P/E. What's in the News PeptiDream issued consolidated earnings guidance for the fiscal year ending December 31, 2026, with expected revenue of ¥32,000 million, core operating profit and operating profit of ¥4,600 million, and profit attributable to owners of parent of ¥3,000 million (Corporate guidance).Narrative-Update • Feb 24
4587: Expanded Oral Pipeline And 2026 Milestones Will Drive Future Upside Potential
Analysts have slightly adjusted their price target on PeptiDream to ¥4,255 from ¥4,281 to reflect updated views on fair value, alongside refreshed assumptions for revenue growth, profit margin, discount rate and future P/E. What's in the News PeptiDream issued consolidated earnings guidance for the fiscal year ending December 31, 2026, expecting revenue of ¥32,000 million, core operating profit and operating profit of ¥4,600 million, and profit attributable to owners of parent of ¥3,000 million.Analyseartikel • Feb 18
Analysts Have Lowered Expectations For PeptiDream Inc. (TSE:4587) After Its Latest Results
There's been a notable change in appetite for PeptiDream Inc. ( TSE:4587 ) shares in the week since its yearly report...Narrative-Update • Feb 09
4587: Oral Autoimmune Pipeline Progress Will Drive Stronger Long Term Outlook
Analysts have trimmed their price target on PeptiDream to reflect a fair value of ¥3,033, down from ¥3,271, as they factor in slightly softer revenue growth and profit margin assumptions, along with a modestly higher discount rate and P/E multiple outlook. What's in the News PeptiDream reported a revision to its fiscal year 2025 guidance, now expecting revenue of ¥18,000 million instead of ¥49,000 million, with an operating loss of ¥5,400 million and a loss attributable to owners of parent of ¥4,000 million, citing delays in anticipated milestones and partnering deals including its oral myostatin program.Narrative-Update • Jan 26
4587: Milestone Progress In RNAi Delivery Platform Will Support Future Upside
Analysts now mark their fair value estimate for PeptiDream at ¥2,600, up from ¥2,500, reflecting adjustments to discount rates, revenue growth assumptions, profit margins, and a higher future P/E multiple. What's in the News PeptiDream reported a preclinical development milestone in its collaboration with Alnylam Pharmaceuticals, supporting a modular platform for precision siRNA delivery using macrocyclic peptides to target organs beyond the liver, with associated milestone payments and potential future royalties from Alnylam products (Key Developments).Narrative-Update • Jan 12
4587: Expanded Pipeline Milestones Will Drive Future Upside Potential
Analysts have reduced their price expectations for PeptiDream, reflecting updated assumptions for slightly lower revenue growth and profit margins, along with a higher future P/E multiple. Together, these changes reduce the implied upside from prior targets on a discounted cash flow basis.Narrative-Update • Dec 17
4587: Rebound In Partnering Revenues Will Drive Strong Upside Potential
Analysts have trimmed their price target on PeptiDream from ¥4,830 to ¥4,281, reflecting a slightly higher discount rate, even as they modestly raise long term revenue growth and profit margin assumptions and apply a lower future P E multiple. What's in the News PeptiDream sharply cut its FY25 revenue guidance to JPY 18 billion from JPY 49 billion, and now expects an operating loss of JPY 5.4 billion instead of a JPY 21.6 billion profit, as milestone and partnering revenues shift into FY26 (company guidance).Analyseartikel • Dec 04
This Just In: Analysts Are Boosting Their PeptiDream Inc. (TSE:4587) Outlook for Next Year
Shareholders in PeptiDream Inc. ( TSE:4587 ) may be thrilled to learn that the analysts have just delivered a major...Narrative-Update • Dec 03
4587: Radiopharmaceutical Pipeline Progress Will Drive Stronger Long Term Outlook
Analysts have modestly reduced their price target on PeptiDream from ¥3,414 to ¥3,271 as they incorporate a slightly higher discount rate, even as they update their assumptions to reflect stronger revenue growth, improved profitability, and a lower future P/E multiple. What's in the News PeptiDream, PDRadiopharma, and Curium have initiated a registrational Phase 2 clinical trial in Japan for 64Cu-PSMA-I&T, a PET radiopharmaceutical targeting PSMA expressed on prostate cancer cells (Key Developments).Analyseartikel • Oct 05
Is PeptiDream (TSE:4587) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Narrative-Update • Sep 05
AI Discovery And Peptide Pipeline Will Expand Horizons
With both the discount rate and future P/E multiple showing only negligible movement, there has been no material change to PeptiDream's consensus analyst fair value, which remains steady at ¥3414. Valuation Changes Summary of Valuation Changes for PeptiDream The Consensus Analyst Price Target remained effectively unchanged, at ¥3414.Analyseartikel • Jun 23
PeptiDream (TSE:4587) Seems To Use Debt Rather Sparingly
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analyseartikel • Apr 17
Here's Why We Think PeptiDream (TSE:4587) Might Deserve Your Attention Today
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
Neues Narrative • Mar 10
Advancements In Radiopharmaceutical Pipeline And Novartis Deal Will Drive Future Success
Expansion of deals and strategic partnerships positions PeptiDream for substantial future revenue growth from clinical advancements and imaging collaborations.Analyseartikel • Mar 08
PeptiDream (TSE:4587) Has A Rock Solid Balance Sheet
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analyseartikel • Feb 19
Bullish: Analysts Just Made A Decent Upgrade To Their PeptiDream Inc. (TSE:4587) Forecasts
Shareholders in PeptiDream Inc. ( TSE:4587 ) may be thrilled to learn that the analysts have just delivered a major...Analyseartikel • Feb 17
Earnings Miss: PeptiDream Inc. Missed EPS By 5.6% And Analysts Are Revising Their Forecasts
It's been a pretty great week for PeptiDream Inc. ( TSE:4587 ) shareholders, with its shares surging 18% to JP¥2,328 in...Analyseartikel • Feb 14
PeptiDream Inc.'s (TSE:4587) Price Is Out Of Tune With Earnings
When close to half the companies in Japan have price-to-earnings ratios (or "P/E's") below 13x, you may consider...Analyseartikel • Dec 22
Are Investors Undervaluing PeptiDream Inc. (TSE:4587) By 39%?
Key Insights Using the 2 Stage Free Cash Flow to Equity, PeptiDream fair value estimate is JP¥4,230 PeptiDream is...Analyseartikel • Nov 21
PeptiDream's (TSE:4587) Performance Is Even Better Than Its Earnings Suggest
Even though PeptiDream Inc.'s ( TSE:4587 ) recent earnings release was robust, the market didn't seem to notice...Analyseartikel • Nov 18
PeptiDream Inc. Just Missed Earnings; Here's What Analysts Are Forecasting Now
It's been a good week for PeptiDream Inc. ( TSE:4587 ) shareholders, because the company has just released its latest...Analyseartikel • Nov 15
Is PeptiDream (TSE:4587) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analyseartikel • Oct 31
PeptiDream Inc.'s (TSE:4587) Price Is Out Of Tune With Earnings
When close to half the companies in Japan have price-to-earnings ratios (or "P/E's") below 13x, you may consider...Analyseartikel • Oct 15
Do PeptiDream's (TSE:4587) Earnings Warrant Your Attention?
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Analyseartikel • Aug 29
PeptiDream Inc. (TSE:4587) Shares Could Be 37% Below Their Intrinsic Value Estimate
Key Insights Using the 2 Stage Free Cash Flow to Equity, PeptiDream fair value estimate is JP¥4,180 Current share price...Analyseartikel • Aug 12
PeptiDream Inc. Just Beat Revenue Estimates By 13%
Shareholders of PeptiDream Inc. ( TSE:4587 ) will be pleased this week, given that the stock price is up 11% to...Analyseartikel • Jun 30
PeptiDream Inc. (TSE:4587) Surges 27% Yet Its Low P/S Is No Reason For Excitement
PeptiDream Inc. ( TSE:4587 ) shares have continued their recent momentum with a 27% gain in the last month alone...Analyseartikel • Jun 02
News Flash: Analysts Just Made A Meaningful Upgrade To Their PeptiDream Inc. (TSE:4587) Forecasts
Celebrations may be in order for PeptiDream Inc. ( TSE:4587 ) shareholders, with the analysts delivering a significant...Analyseartikel • Apr 30
PeptiDream Inc.'s (TSE:4587) 42% Price Boost Is Out Of Tune With Revenues
PeptiDream Inc. ( TSE:4587 ) shares have continued their recent momentum with a 42% gain in the last month alone...Analyseartikel • Apr 29
Is PeptiDream Inc. (TSE:4587) Trading At A 46% Discount?
Key Insights PeptiDream's estimated fair value is JP¥3,010 based on 2 Stage Free Cash Flow to Equity Current share...Analyseartikel • Mar 03
PeptiDream Inc.'s (TSE:4587) 25% Jump Shows Its Popularity With Investors
PeptiDream Inc. ( TSE:4587 ) shareholders would be excited to see that the share price has had a great month, posting a...Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2028 | 44,720 | 10,196 | 7,788 | 7,100 | 6 |
| 12/31/2027 | 41,413 | 9,386 | 6,741 | 6,800 | 6 |
| 12/31/2026 | 36,043 | 6,766 | 2,900 | 5,000 | 6 |
| 6/30/2026 | 19,204 | -3,626 | -5,543 | -4,144 | N/A |
| 3/31/2026 | 19,053 | -3,571 | -5,739 | -4,398 | N/A |
| 12/31/2025 | 18,521 | -3,749 | -15,030 | -13,276 | N/A |
| 9/30/2025 | 17,930 | -5,823 | -14,722 | -12,543 | N/A |
| 6/30/2025 | 19,086 | -5,033 | 13,343 | 15,551 | N/A |
| 3/31/2025 | 46,685 | 14,824 | 13,521 | 15,943 | N/A |
| 12/31/2024 | 46,676 | 15,014 | 21,626 | 23,844 | N/A |
| 9/30/2024 | 47,773 | 17,115 | 25,068 | 27,078 | N/A |
| 6/30/2024 | 55,419 | 21,689 | -780 | 992 | N/A |
| 3/31/2024 | 27,974 | 2,441 | 1,228 | 2,760 | N/A |
| 12/31/2023 | 28,712 | 3,035 | 11,052 | 12,420 | N/A |
| 9/30/2023 | 38,187 | 11,281 | 9,213 | 10,512 | N/A |
| 6/30/2023 | 31,254 | 7,956 | 7,397 | 8,696 | N/A |
| 3/31/2023 | 31,396 | 8,135 | 3,748 | 7,663 | N/A |
| 12/31/2022 | 26,852 | 7,554 | -4,057 | -82 | N/A |
| 9/30/2022 | 12,811 | 57 | -5,082 | -1,376 | N/A |
| 6/30/2022 | 11,511 | 1,705 | -2,483 | 1,687 | N/A |
| 3/31/2022 | 8,326 | 2,341 | 421 | 1,929 | N/A |
| 12/31/2021 | 9,366 | 3,606 | 5,440 | 6,655 | N/A |
| 9/30/2021 | 15,607 | 7,110 | 5,229 | 6,447 | N/A |
| 6/30/2021 | 11,449 | 4,329 | 4,869 | 5,368 | N/A |
| 3/31/2021 | 12,743 | 5,226 | 5,643 | 6,111 | N/A |
| 12/31/2020 | 11,677 | 4,448 | 1,146 | 1,733 | N/A |
| 12/31/2019 | 2,075 | -977 | N/A | 484 | N/A |
| 6/30/2019 | 7,217 | 2,770 | N/A | 4,481 | N/A |
| 6/30/2018 | 6,427 | 2,335 | N/A | 1,023 | N/A |
| 3/31/2018 | 4,616 | 895 | N/A | 623 | N/A |
| 9/30/2017 | 4,271 | 962 | N/A | 517 | N/A |
| 6/30/2017 | 4,896 | 1,891 | N/A | 1,531 | N/A |
| 3/31/2017 | 3,064 | 769 | N/A | 1,095 | N/A |
| 12/31/2016 | 4,457 | 1,685 | N/A | 2,338 | N/A |
| 9/30/2016 | 4,735 | 1,823 | N/A | 2,844 | N/A |
| 6/30/2016 | 4,328 | 1,581 | N/A | 1,533 | N/A |
| 3/31/2016 | 4,620 | 1,976 | N/A | 2,027 | N/A |
| 12/31/2015 | 3,121 | 1,203 | N/A | 1,216 | N/A |
| 9/30/2015 | 2,722 | 1,063 | N/A | 834 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: 4587 wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (0.9%).
Ertrag vs. Markt: 4587 wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.
Hohe Wachstumserträge: 4587 wird voraussichtlich in den nächsten 3 Jahren rentabel werden.
Einnahmen vs. Markt: 4587Die Einnahmen des Unternehmens (18.3% pro Jahr) werden voraussichtlich schneller wachsen als der Markt JP (6.4% pro Jahr).
Hohe Wachstumseinnahmen: 4587Die Einnahmen des Unternehmens (18.3% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: 4587Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (11%).
Wachstumsunternehmen entdecken
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/09/17 17:53 |
| Aktienkurs zum Tagesende | 2026/09/17 00:00 |
| Gewinne | 2026/06/30 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das , das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
PeptiDream Inc. wird von 14 Analysten beobachtet. 6 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Shan He | Bernstein |
| Hidemaru Yamaguchi | Citigroup Inc |
| Kazuaki Hashiguchi | Daiwa Securities Co. Ltd. |